Association between schizophrenia and metabolic diseases
DOI:
https://doi.org/10.34119/bjhrv8n4-261Keywords:
schizophrenia, metabolic syndrome, risk factors, antipsychotic agents, glucose metabolism disordersAbstract
Schizophrenia is a chronic psychiatric disorder that has been increasingly associated with a higher prevalence of metabolic diseases, a relationship that may compromise treatment outcomes and quality of life. Understanding this association is essential for improving clinical management and preventive strategies. This study aims to identify the main factors that link schizophrenia and metabolic conditions, as well as to discuss how metabolic alterations may influence the course and treatment of the disorder. To this end, a integrative review was conducted, analyzing national and international scientific publications published between 2017 and 2023. The search was performed in the Virtual Health Library (VHL) and Scientific Electronic Library Online (SciELO) databases, and included one article from The Research, Society and Development Journal. The results indicate that the most relevant factors correlating schizophrenia and metabolic diseases include the prolonged use of antipsychotics, endocrine and/or immunological disorders, genetic predisposition, and unhealthy lifestyle habits common among individuals with schizophrenia. It is observed that the relationship between these conditions is bidirectional: schizophrenia can increase the risk of developing metabolic alterations, and, conversely, the presence of such alterations can worsen symptoms and complicate treatment. This interaction has important clinical implications, reinforcing the need for integrated care approaches that address both mental health and metabolic health in this population.
References
AGUIAR-BLOEMER, A.C.; AGLIUSSI, R.G.; PINHO, T.M.P.; FURTADO, E.F.; DIEZ-GARCIA, R.W. Eating behavior of schizophrenic patients. Revista de Nutrição, v.31, p.13-24, jan. 2018.
AMARAL, L.P. Efeitos da leptina na adipogênese e produção de mediadores inflamatórios por adipócitos 3T3-l1. 2017. 90 pages. Master's thesis (Cellular and Molecular Biology) – Fundação Oswaldo Cruz, Rio de Janeiro, 2024.
AMERICAN PSYCHIATRIC ASSOCIATION. Espectro da esquizofrenia e outros transtornos psicóticos. In: Manual Diagnostico e Estatístico de Transtornos Mentais: DSM-5. Porto Alegre: Artmed Editora S.A., 2011, p.87-122.
ARYSTARKHOVA, E.; LIU, Y.B.; SALAZAR, C.; STANOJEVIC, V.; CLIFFORD, R.J.; KAPLAN, J.H.; KIDDER, G.M.; SWEADNER, K.J. Hyperplasia of pancreatic beta cells and improved glucose tolerance in mice deficient in the FXYD2 subunit of Na,K-ATPase. Journal of Biological Chemistry, v.288, p.7077-7085, mar. 2013.
BOIKO, A.S.; POZHIDAEV, I.V.; PADERINA, D.Z.; MEDNOVA, I.A.; GONCHAROVA, A.A.; FEDORENKO, O.Y.; KORNETOVA, E.G.; SEMKE, A.V.; BOKHAN, N.A.; LOONEN, A.J.M.; IVANOVA, S.A. Gene polymorphisms of hormonal regulators of metabolism in patients with schizophrenia with metabolic syndrome. Genes, v.13, p.844, maio 2022.
BORGES NETO, J.S.; BICALHO, J.M.F.; SILVA, T.M.; VIEIRA, M.S.; BILA, W.C.; FREITAS, P.H.B.; MACHADO, R.M.; GRANJEIRO, P.A. Frequency of metabolic syndrome in schizophrenic patients. Research, Society and Development, v.10, nov. 2021.
BOUCHER, J.; KLEINRIDDERS, A.; KAHN, C.R. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harbor Perspectives in Biology, v.6, jun. 2014.
CADENHEAD, K.S.; MINICHINO, A.; KELSVEN, S.; ADDINGTON, J.; BEARDEN, C.; CANNON, T.D.; CORNBLATT, B.A.; MATHALON, D.; McGLASHAN, T.H.; PERKINS, D.O.; SEIDMAN, L.J.; TSUANG, M.; WALKER, E.F.; WOODS, S.W.; YAO, J.; NORTH AMERICAN PRODROMAL LONGITUDINAL STUDIES (NAPLS) CONSORTIUM. Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: findings from the North American Prodrome Longitudinal Studies Consortium. Schizophrenia Research, v.204, p.96-103, jan. 2019.
ÇAKICI, N.; SUTTERLAND, A.L.; PENNINX, B.W.J.H.; DALM, V.A.; DE HAAN, L.; VAN BEVEREN, N.J.M. Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. Brain, Behavior, and Immunity, v.88, p.547-558, jul. 2020.
CERF, M.E. Beta cell dysfunction and insulin resistance. Frontiers in Endocrinology, v.4, p.37, mar. 2013.
CHOI, K.M.; RYU, O.H.; LEE, K.W.; KIM, H.Y.; SEO, J.A.; KIM, S.G.; KIM, N.H.; CHOI, D.S.; BAIK, S.H. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Research and Clinical Practice, v.75, p.235-240, ago. 2007.
DA SILVA, D.G.C.; KANAZAWA, L.K.S.; VECCHIA, D.D. Schizophrenia: effects of aripiprazole in metabolic syndrome. Brazilian Journal of Pharmaceutical Sciences, v.55, abr./jun. 2019.
DE MEYTS, P. The insulin receptor and its signal transduction network. In: FEINGOLD, K.R.; AHMED, S.F.; ANAWALT, B., et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Updated 27 Apr 2016.
DE SOUSA, R.T.; SERPA, M.H. Schizophrenia and other psychotic disorders. In: SAMPAIO, L.A.N.P.C.; NETO, F.L., editors. Psychiatry — The Essentials. São Paulo: Qualivida Editora de Livros e Periódicos, 2018, p.71-84.
DING, H.; OUYANG, M.; WANG, J.; XIE, M.; HUANG, Y.; YUAN, F.; JIA, Y.; ZHANG, X.; LIU, N.; ZHANG, N. Shared genetics between classes of obesity and psychiatric disorders: a large-scale genome-wide cross-trait analysis. Journal of Psychosomatic Research, v.162, jan. 2022.
ESFAHANI, M.; MOVAHEDIAN, A.; BARANCHI, M.; GOODARZI, M.T. Adiponectin: an adipokine with protective features against metabolic syndrome. Iranian Journal of Basic Medical Sciences, v.18, p.430-442, ago. 2015.
FAHED, G.; AOUN, L.; BOU ZERDAN, M.; ALLAM, S.; BOU ZERDAN, M.; BOUFERRAA, Y.; ASSI, H.I. Metabolic syndrome: updates on pathophysiology and management in 2021. International Journal of Molecular Sciences, v.23, p.786, fev. 2022.
FISMAN, E.Z.; TENENBAUM, A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovascular Diabetology, v.13, p.103, dez. 2014.
FREEMAN, A.M.; ACEVEDO, L.A.; PENNINGS, N. Insulin resistance. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 17 Aug 2023.
GOH, K.K.; CHEN, C.Y.; WU, T.H.; CHEN, C.H.; LU, M.L. Crosstalk between schizophrenia and metabolic syndrome: the role of oxytocinergic dysfunction. International Journal of Molecular Sciences, v.23, p.7092, jul. 2022.
GRUNDY, S.M.; BREWER JR, H.B.; CLEEMAN, J.I.; SMITH JR, S.C.; LENFANT, C.; AMERICAN HEART ASSOCIATION; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, v.109, p.433-438, jan. 2004.
HALLAK, J.E.C.; CHAVES, C.; ZUARDI, A.W. Esquizofrenia. In: KAPCZINSKI, F.; QUEVEDO, J.; IZQUIERDO, I., editors. Bases biológicas dos transtornos psiquiátricos: uma abordagem translacional. Porto Alegre: Artmed Editora S.A., 2011, p.195-210.
HANSSEN, R.; AUWERX, C.; JÕELOO, M.; SADLER, M.C.; ESTONIAN BIOBANK RESEARCH TEAM; HENNING, E.; KEOGH, J.; BOUNDS, R.; SMITH, M.; FIRTH, H.V.; KUTALIK, Z.; FAROOQI, I.S.; REYMOND, A.; LAWLER, K. Chromosomal deletions on 16p11.2 encompassing SH2B1 are associated with accelerated metabolic disease. Cell Reports Medicine, v.4, fev. 2023.
HELALY, A.M.N.; GHORAB, D.S.E.D. Schizophrenia as metabolic disease: what are the causes? Metabolic Brain Disease, v.38, p.795-804, jan. 2023.
JUNIOR, D.L.; DE ALMEIDA, J.M.; JÚNIOR, I.S.M.; NASCIMENTO, I.S.; SOARES, P.F.S.; VALENTIN, F.N. Schizophrenia overview and treatment expectations. Brazilian Journal of Health Review, v.4, p.22624–22633, 2021.
KIM, S.W.; KANG, H.J.; JHON, M.; KIM, J.W.; LEE, J.Y.; WALKER, A.J.; AGUSTINI, B.; KIM, J.M.; BERK, M. Statins and inflammation: new therapeutic opportunities in psychiatry. Frontiers in Psychiatry, v.10, p.103, mar. 2019.
LOBO, L.; MAIA, L.A.C.R. Reabilitação / Estimulação neuropsicológica na esquizofrenia. Revista Psicologia em Foco, v.13, p.2-20, jan. 2021.
LV, H.; LI, J.; GAO, K.; ZENG, L.; XUE, R.; LIU, X.; ZHOU, C.; YUE, W.; YU, H. Identification of genetic loci that overlap between schizophrenia and metabolic syndrome. Psychiatry Research, v.314, fev. 2022.
MAZEREEL, V.; DETRAUX, J.; VANCAMPFORT, D.; VAN WINKEL, R.; DE HERT, M. Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Frontiers in Endocrinology, v.11, dez. 2020.
MIZUKI, Y.; SAKAMOTO, S.; OKAHISA, Y.; YADA, Y.; HASHIMOTO, N.; TAKAKI, M.; YAMADA, N. Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. International Journal of Neuropsychopharmacology, v.24, p.367-382, abr. 2021.
NOH, K.; PARK, J.C.; HAN, J.S.; LEE, S.J. From bound cells comes a sound mind: the role of neuronal growth regulator 1 in psychiatric disorders. Experimental Neurobiology, v.29, p.1-10, jan. 2020.
O'DONOGHUE, B.; ALLOTT, K.; HARRIGAN, S.; SCALZO, F.; WARD, J.; MALLAWAARACHCHI, S.; WHITSON, S.; BALDWIN, L.; GRAHAM, J.; MULLEN, E.; MACNEIL, C.; ALEXANDER, D.; WOOD, S.J.; BERK, M.; ALVAREZ-JIMENEZ, M.; THOMPSON, A.; FORNITO, A.; YUEN, H.P.; NELSON, B.; FRANCEY, S.M.; MCGORRY, P. Isolating the impact of antipsychotic medication on metabolic health: secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study). Early Intervention in Psychiatry, v.17, p.597-607, jun. 2023.
PETERS, T.; NÜLLIG, L.; ANTEL, J.; NAARESH, R.; LAABS, B.H.; TEGELER, L.; AMHAOUACH, C.; LIBUDA, L.; HINNEY, A.; HEBEBRAND, J. The role of genetic variation of BMI, body composition, and fat distribution for mental traits and disorders: a look-up and Mendelian randomization study. Frontiers in Genetics, v.11, p.373, mai. 2020.
PRESTWOOD, T.R.; ASGARIROOZBEHANI, R.; WU, S.; AGARWAL, S.M.; LOGAN, R.W.; BALLON, J.S.; HAHN, M.K.; FREYBERG, Z. Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behavioural Brain Research, v.398, jan. 2021.
ROCHLANI, Y.; POTHINENI, N.V.; KOVELAMUDI, S.; MEHTA, J.L. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic Advances in Cardiovascular Disease, v.11, p.215-225, mar. 2017.
SAKLAYEN, M.G. The global epidemic of the metabolic syndrome. Current Hypertension Reports, v.20, p.12, jan. 2018.
SALTIEL, A.R. Insulin signaling in health and disease. Journal of Clinical Investigation, v.131, jan. 2021.
SARAIVA, M.; VIEIRA, P.; O'GARRA, A. Biology and therapeutic potential of interleukin-10. Journal of Experimental Medicine, v.217, abr. 2020.
SCHERÜBL, H. Metabolic syndrome and cancer risk. Deutsche Medizinische Wochenschrift, v.147, p.1068-1077, jul. 2022.
SHEN, H.; LI, R.; YAN, R.; ZHOU, X.; FENG, X.; ZHAO, M.; XIAO, H. Adjunctive therapy with statins in schizophrenia patients: a meta-analysis and implications. Psychiatry Research, v.262, p.84-93, abr. 2018.
SHI, J.; FAN, J.; SU, Q.; YANG, Z. Cytokines and abnormal glucose and lipid metabolism. Frontiers in Endocrinology, v.10, p.703, jul. 2019.
SOMMER, I.E.; GANGADIN, S.S.; DE WITTE, L.D.; KOOPS, S.; VAN BAAL, C.; BAHN, S.; DREXHAGE, H.; VAN HAREN, N.E.M.; VELING, W.; BRUGGEMAN, R.; MARTENS, P.; WIERSMA, S.; VEERMAN, S.R.T.; GROOTENS, K.P.; VAN BEVEREN, N.; KAHN, R.S.; BEGEMANN, M.J.H. Simvastatin augmentation for patients with early-phase schizophrenia-spectrum disorders: a double-blind, randomized placebo-controlled trial. Schizophrenia Bulletin, v.47, p.1108-1115, jul. 2021.
STEARNS, F.W. One hundred years of pleiotropy: a retrospective. Genetics, v.186, p.767-773, mar. 2010.
SWARUP, S.; AHMED, I.; GRIGOROVA, Y., et al. Metabolic syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 7 Mar 2024.
TEIXEIRA, P.J.R.; ROCHA, F.L. Associação entre síndrome metabólica e transtornos mentais. Archives of Clinical Psychiatry, v.34, p.28–38, jan. 2007.
VARGAS, T.S.; SANTOS, Z.E.A. Prevalence of metabolic syndrome in schizophrenic patients. Scientia Médica, v.21, p.4-8, jan. 2011.
VEGA, G.L.; WANG, J.; GRUNDY, S.M. Utility of metabolic syndrome as a risk enhancing factor in decision of statin use. Journal of Clinical Lipidology, v.15, p.255-265, mar. 2021.
VON FRANKENBERG, A.D.; REIS, A.F.; GERCHMAN, F. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review. Archives of Endocrinology and Metabolism, v.61, p.614–622, out. 2017.
WORLD HEALTH ORGANIZATION. ICD-11 for Mortality and Morbidity Statistics. World Health Organization, Geneva, 2022. Disponível em: https://icd.who.int/browse/2024-01/mms/en. Acesso em: 14 fev. 2024.
ZURRÓN MADERA, P.; CASAPRIMA SUÁREZ, S.; GARCÍA ÁLVAREZ, L.; GARCÍA-PORTILLA GONZÁLEZ, M.P.; JUNQUERA FERNÁNDEZ, R.; LLUCH CANUT, M.T. Eating and nutritional habits in patients with schizophrenia. Revista de Psiquiatría y Salud Mental (English Edition), v.15, n.1, p.54-60, jan./mar. 2022.
